Dr Williams completed his undergradute studies in Birmingham, before moving to London where he trained at the Hammersmith Hospital. He completed his clinical oncology training in London, followed by a PhD with the Advanced Computation Lab at CRUK/UCL. He was appointed as a Consultant at Imperial College Healthcare NHS Trust in February 2012, where he specialises in neuro-oncology and is joint MDT lead for neuro-oncology. He is an Honorary Senior Fellow at Imperial College, where he leads the Computational Oncology Group. He sits on the NCRI Brain Tumour clinical trials group, and has a particular interest in studies looking at novel approaches to improving current treatments in neuro-oncology. He chairs the neuro-oncology MDT at The London Clinic, and has worked to make The London Clinic the only site in the UK that offers the INTRAGO-II trial (Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme) Dr. Williams' current clinical focus is on the delivery of novel drugs and drug/radiotherapy combinations for patients with primary and metastatic brain tumours. He took part in the first UK expanded access scheme to use Optune widely, and runs the UK's largest Optune clinic. Dr Matthews is one of the few people experienced across all three main stereotactic modalities (Gamma Knife, Cyberknife, and LINAC-based SRS). He also helped found the Advanced Therapies Group at Imperial, which explores the integration of cutting-edge research and clinical practice to deliver novel therapies to patients with brain tumours. Dr Williams supervises a range of PhD/MD students with Imperial College researching and studying projects. He teaches about brain tumours on a European course in oncology and led the London ICR course module on brain tumours for several years.